Sign up
Log in
OrbiMed Advisors acquires Q32 Bio common shares worth $15 million in private placement
Share
Listen to the news
OrbiMed Advisors acquires Q32 Bio common shares worth $15 million in private placement
  • OrbiMed Advisors, a director and 10% owner, bought 1.88 million Q32 Bio common shares in a private placement at USD 8 each.
  • Indirect beneficial ownership rose to 3.5 million shares held via OrbiMed Private Investments VII.
  • A separate OrbiMed Genesis position totaled 625,000 shares following the purchase.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000947871-26-000593), on June 01, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved